China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in a Phase I clinical study of its GT20029 for androgenetic alopecia and acne in China. The randomized, double-blind, placebo-controlled study assessed the safety and pharmacokinetics of GT20029 (gel / tincture) in healthy subjects via single or multiple doses of topical administration. The company expects to lock the database for data analysis during the fourth quarter of 2022.
Drug Details
GT20029 is described by Kintor as the world’s first external use compound based on proteolytic targeting chimera (PROTAC) technology. Excessive activation of the androgen receptor (AR) pathway is a key factor in the development of androgenetic alopecia and acne. GT20029 can effectively block the androgen receptor signaling pathway and its physiological functions by degrading the androgen receptor protein. The drug exerts local therapeutic effects while reducing systemic drug exposure and avoiding side effects associated with oral therapeutic drugs. GT20029 has received clinical study approval to treat androgenetic alopecia and acne in the US and China, with the first patient dosed in July 2021. The first patient dosing in a Phase I study in the US was completed in February this year.-Fineline Info & Tech
